Sunesis Pharmaceuticals to Present at the Wells Fargo Securities 2018 Healthcare Conference
August 30 2018 - 6:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that
Willie Quinn, Chief Financial Officer and Senior Vice President,
Finance and Corporate Development of Sunesis, will present at the
Wells Fargo Securities 2018 Healthcare Conference on Thursday,
September 6, 2018 at 10:20 A.M. Eastern Time at the Westin Copley
Place in Boston,
MA. A
live webcast of the presentation will be available on the Sunesis
website at http://ir.sunesis.com. A replay will be archived
on the "Calendar of Events" page in the Investors and Media section
of the Sunesis website for two weeks.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company
developing new therapeutics for the treatment of hematologic and
solid cancers. Sunesis has built an experienced drug development
organization committed to improving the lives of people with
cancer. The Company is focused on advancing its novel
kinase-inhibitor pipeline, with an emphasis on establishing proof
of concept that its oral non-covalent BTK-inhibitor vecabrutinib is
effective in ibrutinib-resistant chronic lymphocytic leukemia.
Vecabrutinib is currently being evaluated in a Phase 1b/2 study in
adults with chronic lymphocytic leukemia and other B-cell
malignancies who have progressed after prior therapies. Beyond the
development of vecabrutinib, the Company has two other kinase
inhibitor programs, including Sunesis’ proprietary preclinical PDK1
inhibitor SNS-510, which is in preclinical development with an IND
submission planned in 2019, and the Takeda-partnered pan-RAF
inhibitor TAK-580, which is in a clinical trial for pediatric
low-grade glioma. PDK1 is a master kinase that activates
other kinases important to cell growth and survival including
members of the AKT, PKC, RSK and SGK families. Sunesis is also
seeking a partner to fund the completion of development for
vosaroxin, a Phase 3 investigational product for relapsed or
refractory AML.
For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis
Pharmaceuticals, Inc.
Investor and Media Inquiries:Maeve ConneightonArgot
Partners212-600-1902
Willie QuinnSunesis Pharmaceuticals Inc.650-266-3716
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Sunesis Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles